GlaxoSmithKline marks 40 years of clinical evidence supporting Corsodyl

GlaxoSmithKline has hailed the 40th anniversary of the publication of the first clinical evidence supporting its well-established medicated mouthwash Corsodyl.

The first clinical evidence supporting the dental application of the chlorhexidine digluconate formulation emerged four decades ago, and since then Corsodyl has become the most recommended medicated mouthwash by dental experts in the UK.

Chlorhexidine digluconate is a double-positively-charged molecule, enabling it to bind to negatively-charged surfaces including teeth, mucous membranes and bacteria. It then repels bacteria by creating a protective shield over the teeth and gums.

Because of this substantivity, chlorhexidine is available for up to 12 hours post-rinsing, meaning it provides long-lasting protection against bacteria.

Corsodyl is currently recommended for a range of applications, including treating gingivitis, supporting oral health in compromised patients, protecting gum healing after surgery, resolving denture stomatitis and healing acute candidiasis.

It is one of a number of leading dental brands in GlaxoSmithKline's portfolio, alongside Aquafresh, Sensodyne, Biotene and Poligrip.